Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Amine Kasmi, Borhane Slama et al.|Nature Medicine|2024Cited by 109
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trialSalomon Manier, Thierry Façon, Jérôme Lambert et al.|The Lancet Oncology|2025Cited by 13
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 studyArthur Bobin, Xavier Leleu, Salomon Manier et al.|Haematologica|2024Cited by 3
A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: The IFM2017-03 Phase 3 TrialSalomon Manier, Thierry Façon, Jérôme Lambert et al.|SSRN Electronic Journal|2025Cited by 1
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01Arthur Bobin, Xavier Leleu, Salomon Manier et al.|Blood|2023Cited by 0